Celiac Plexus Neurolysis Relieves Pancreatic Cancer Pain

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 8 No 8
Volume 8
Issue 8

ORLANDO-The delivery of neurolytic chemicals to the celiac plexus, guided by endoscopic ultrasound, has been shown to be an effective, convenient, and safe technique to provide pain relief for pancreatic cancer patients.

ORLANDO—The delivery of neurolytic chemicals to the celiac plexus, guided by endoscopic ultrasound, has been shown to be an effective, convenient, and safe technique to provide pain relief for pancreatic cancer patients.

At the Digestive Disease Week meeting, gastroenterologist Marc Catalano, MD, described the findings from a study done at the Pancreatic Biliary Center, St. Lukes Medical Center, Milwaukee. The research involved 16 patients with unresectable pancreatic cancer and intractable pain.

“In the past, this kind of pain has been managed with narcotics,” Dr. Catalano said, “or the celiac plexus nerve has been destroyed percutaneously, with the drugs injected under the guidance of CT scan.” However, this region is difficult to locate under CT guidance, he said, in part because of all the tissue that the needle must traverse. Also, the CT scan, being an external modality, offers only fuzzy images, he added.

Complications of percutaneous delivery of the neurolytic drugs with CT guidance have included bleeding and paralysis, through accidental destruction of nearby spinal nerves.

“It’s easy to precisely identify the target structures with endoscopic ultrasound, which brings the transducer right into the area,” Dr. Catalano said. Alcohol is then injected to deaden the nerves causing the pain. He noted that this method was pioneered by Dr. Maurits Wiersema of the Mayo Clinic and by Dr. Frank Gress of Winthrop University Hospital, Mineola, New York.

In this study, patients were asked to rank their pain on a scale of 10 both before and after the procedure. The researchers obtained post-procedure pain scores at 2, 4, 8, and 12 weeks. While the mean pain score was 7.8 before the block, by 12 weeks it had dropped to 1.5. Eleven of 13 patients (85%) followed at 12 weeks had also reduced their pain medication. Three patients experienced mild diarrhea, which was treated successfully with medication.

Physicians can stage pancreatic cancer patients and treat their pain simultaneously using an endoscopic ultrasound probe, Dr. Catalano said. “For the experienced endosonographer who does fine-needle aspiration, there is little or no learning curve involved with this method,” he added.

Related Videos
Tailoring neoadjuvant therapy regimens for patients with mismatch repair deficient gastroesophageal cancer represents a future step in terms of research.
Not much is currently known about the factors that may predict pathologic responses to neoadjuvant immunotherapy in this population, says Adrienne Bruce Shannon, MD.
The toxicity profile of tislelizumab also appears to look better compared with chemotherapy in metastatic esophageal squamous cell carcinoma.
Patients with unresectable or metastatic esophageal squamous cell carcinoma and higher PD-L1 expression may benefit from treatment with tislelizumab, according to Syma Iqbal, MD.
Quantifying disease volume to help identify potential recurrence following surgery may be a helpful advance, according to Sean Dineen, MD.
Tanios S. Bekaii-Saab, MD, and the Oncology Brothers presenting slides
Tanios S. Bekaii-Saab, MD, and the Oncology Brothers presenting slides
Tanios S. Bekaii-Saab, MD, and the Oncology Brothers presenting slides
Tanios S. Bekaii-Saab, MD, and the Oncology Brothers presenting slides
Adrienne Bruce Shannon, MD, discussed ways to improve treatment and surgical outcomes for patients with dMMR gastroesophageal cancer.